Novartis India Ltd Gains 8.88%: 4 Key Factors Driving the Week’s Momentum

4 May: Downgrade to Sell Amid Mixed Financial and Technical Signals

Novartis India Ltd was downgraded from a Hold to a Sell rating by MarketsMOJO on 4 May 2026, reflecting concerns over deteriorating quarterly financial performance and a shift in technical indicators. The stock closed at Rs.1,021.90 on the day, down 1.06% from the previous close. The downgrade was driven by a 36.8% decline in net profit after tax to ₹16.09 crores for Q3 FY25-26 and a 7.63% drop in net sales to ₹85.90 crores, signalling operational challenges. Despite a net-debt-free balance sheet and strong long-term operating profit growth of 57.68% annualised, recent quarterly results raised caution.

Valuation metrics also contributed to the downgrade, with the stock trading at a price-to-book ratio of 3.3 against a return on equity of 12.5%, indicating an expensive valuation relative to earnings growth. The price-to-earnings growth ratio of 2.1 further suggested that earnings growth may not fully justify the current price. Domestic mutual funds’ minimal stake of 0.01% underscored limited institutional conviction. Technically, the stock’s momentum softened from bullish to mildly bullish, with mixed signals from MACD, RSI, Bollinger Bands, and other oscillators.

5 May: Technical Momentum Shifts to Mildly Bullish Amid Mixed Signals

On 5 May, Novartis India Ltd closed higher at Rs.1,038.10, gaining 1.59% despite the Sensex declining 0.09%. The technical outlook showed a nuanced picture: the MACD remained bullish on weekly and monthly charts, but the monthly RSI was bearish, indicating potential weakening momentum. Bollinger Bands suggested mild bullishness, while the Know Sure Thing oscillator was bullish weekly but bearish monthly. Dow Theory and On-Balance Volume indicators showed no clear trend, reflecting uncertainty in directional conviction.

Relative to the Sensex, the stock continued to outperform, with a year-to-date return of 31.18% versus the Sensex’s negative 9.33%. However, the downgrade to a Sell rating and mixed technical signals advised caution despite the short-term price resilience.

7 May: Technical Momentum Upgrades to Bullish with Positive Price Action

The stock continued its upward trajectory on 7 May, closing at Rs.1,065.45, up 1.40% from the previous day. Technical momentum improved from mildly bullish to bullish, supported by strong MACD and Bollinger Bands signals on weekly and monthly charts. Daily moving averages remained bullish, reinforcing short-term buying interest. However, the monthly RSI remained bearish, suggesting caution over longer-term momentum. The Know Sure Thing indicator was bullish weekly and mildly bullish monthly, while Dow Theory and On-Balance Volume indicators remained neutral.

Novartis India Ltd’s price returns outpaced the Sensex across multiple timeframes, including a 1.61% gain over the past week versus the Sensex’s 0.60%. Year-to-date and one-year returns were notably strong at 34.88% and 34.31%, respectively, compared to negative returns for the Sensex. Despite the technical upgrade, the Mojo Grade remained at Sell, reflecting ongoing fundamental and valuation concerns.

8 May: New 52-Week High at Rs.1116 Amid Strong Momentum

Novartis India Ltd reached a new 52-week high of Rs.1116 on 8 May 2026, closing at Rs.1,112.60, a 4.43% gain on the day. This marked the fourth consecutive session of gains, cumulatively rising 9.01% over this period. The stock outperformed its Pharmaceuticals & Biotechnology sector by 4.62% despite the Sensex falling 0.40%. The price advanced above all key moving averages, signalling a broad-based bullish trend across short, medium, and long-term timeframes.

Technical indicators such as MACD and Bollinger Bands remained bullish on weekly and monthly charts, while the Know Sure Thing and Dow Theory oscillators ranged from mildly bullish to bullish. The monthly RSI continued to show a bearish signal, suggesting some caution for longer-term momentum. Over the past year, the stock delivered a 40.14% return, significantly outperforming the Sensex’s 3.68% decline. The stock’s strong recovery from its 52-week low of Rs.750 underscores its recent resilience.

Daily Price Comparison: Novartis India Ltd vs Sensex

Key Takeaways

Positive Signals: Novartis India Ltd’s stock demonstrated strong price momentum, gaining 8.88% over the week and outperforming the Sensex by 7.63%. The attainment of a new 52-week high at Rs.1116 and sustained gains over four consecutive sessions highlight robust buying interest. Technical indicators such as MACD and Bollinger Bands consistently signalled bullish momentum, supported by daily moving averages. The stock’s year-on-year return of 40.14% further underscores its resilience amid a mixed market environment.

Cautionary Signals: Despite the price strength, the downgrade to a Sell rating by MarketsMOJO reflects concerns over deteriorating quarterly financials, including a 36.8% drop in PAT and a 7.63% decline in net sales. Valuation metrics suggest the stock is expensive relative to earnings growth and return on equity. Monthly RSI and some momentum oscillators remain bearish, indicating potential medium- to long-term caution. Neutral volume-based indicators and mixed technical signals advise vigilance for possible consolidation or correction phases.

Conclusion

Novartis India Ltd’s week was marked by a compelling price rally, technical momentum upgrades, and a new 52-week high, reflecting strong short-term investor interest. However, the fundamental backdrop remains mixed, with recent quarterly earnings declines and a cautious valuation profile prompting a downgrade to Sell. The divergence between bullish short-term technical indicators and bearish longer-term signals suggests a complex outlook. Investors should carefully weigh the stock’s impressive recent gains against the underlying financial challenges and mixed technical signals when considering their positions.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today